← Patent-cliff monitor small molecule VABOMERE MEROPENEM; VABORBACTAM
Loss of exclusivity April 2039 latest FDA-listed patent expiry
Company REMPEX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS LLC
Drug detail Brand name VABOMERE Active ingredient MEROPENEM; VABORBACTAM Strength 1GM/VIAL;1GM/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval August 2017 Marketing status RX
Listed patents Patent Expires Type 11376237 April 2039 use U-3421 12533342 April 2039 use U-3421 12478606 January 2038 use U-3421 8680136 August 2031 substance, product 12171772 August 2031 substance 9694025 August 2031 use U-2120 10172874 August 2031 product 10561675 August 2031 use U-2490 10183034 August 2031 use U-2490 11007206 August 2031 use U-3128
Regulatory exclusivity Code Expires GAIN August 2027 NCE August 2022
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.